Research Article Details
Article ID: | A12450 |
PMID: | 30451987 |
Source: | Eur J Clin Nutr |
Title: | Diet with greater inflammatory potential is associated with higher prevalence of fatty liver among US adults. |
Abstract: | The prevalence of non-alcoholic fatty liver disease (NAFLD) is rising-caused, at least in part, by unhealthy lifestyles including poor dietary choices. We examined the link between the inflammatory potential of diet as measured by the Dietary Inflammatory Index (DII®) and liver function tests [summarised by the fatty liver index (FLI)]. Of 20,643 US NHANES participants, 48.7% were men and the mean age was 47.3 years. Significant associations were apparent between increasing DII score and prevalent fatty liver. Individuals in the fourth DII quartile had nearly a six-fold higher likelihood of fatty liver [odds ratio (OR) = 5.97, 95% confidence interval: 4.44-8.02] compared with those in the first quartile. Moderation analysis indicated a significant impact of adiposity on the link between FLI and DII score (p < 0.001). This study provides further evidence of an association between the inflammatory potential of diet and fatty liver. |
DOI: | 10.1038/s41430-018-0364-y |

Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Diseases ID | DO ID | Disease Name | Definition | Class |
---|
Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
---|---|---|---|---|---|---|---|
D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |